From the Journals

saRNA Injection Targets Cardiac Injury

Preclinical study shows saRNA therapy improved cardiac function and reduced infarct size after myocardial infarction

  • March 17, 2026

  • 2 min

Share

A novel self-amplifying RNA (saRNA) therapy has been developed to aid heart recovery after myocardial infarction. Researchers demonstrated that a single intramuscular injection of saRNA, which encodes natriuretic peptide type A, allows for sustained hormone production, promoting cardiac recovery for over four weeks in preclinical models, including those with diabetes and atherosclerosis. This simpler approach offers a significant advantage over invasive methods, emphasizing early intervention to bolster heart repair. Future studies will focus on safety and human trials.

Original Source(s)

saRNA Injection Targets Cardiac Injury

  • March 17, 2026

Related Content

Premature Menopause Tied to Higher Lifetime CHD Risk

Lifetime risk estimates evaluated by menopause timing.

Proteomic Profiling Defines Vascular Cell States

Label-free LC–MS profiles nearly 5,000 cells, resolving smooth muscle subtypes and disease-associated phenotypes 

  • March 18, 2026

  • 2 min
Guideline Reclassifies 11% of Patients With Stage 1 Hypertension

Risk-based criteria reduced automatic treatment eligibility among older adults without high-risk comorbidities.